- Scientific advice
- mAb generation & engineering
- Antibody Bioproduction
- ADC's
- Bispecific antibodies

- In vitro immunopharmacology
  - Direct Cytotoxicity Assays
  - Cell-Mediated Cytotoxicity
  - Immune Modulation Assays
  - Available Cell Lines

- In vivo immunopharmacology
  - Mouse Models for Cancer
  - PD1/CTLA4-based Combination Models
  - Mouse Models for Inflammation
  - Antibody Bioanalysis & Safety
  - Efficacy Readouts

- Mouse genetic engineering

Contact

Wish to get more information about our solutions to develop your ADC candidate surely and efficiently?

Contact our business team at contact@mimabs.com or +33 675177351

https://www.mimabs.org/

117 Av de Luminy 13009 Marseille, France

Testimonial

Jack Elands PhD, founder and former Chief Executive Officer of Emergence Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

"Emergence Therapeutics was founded on the basis of ETx-22, a next-generation nectin-4 ADC. The collaboration with MImAbs has been absolutely essential for Emergence's success. MImAbs continues to be a valued partner and collaborator for most of our on-going R&D for ETx-22 and our other ADC projects and has generated critical data enabling our successful series A financing in 2021 as well as our recent acquisition."

ADC DEVELOPMENT: A STEP-BY-STEP PROGRAM TOWARDS SUCCESS

Developing an Antibody-Drug Conjugate (ADC) that shows clinical promise is a challenging step-by-step process that involves a combination of scientific, technical, regulatory, and strategic considerations. Our scientific team brings all its expertise to the early-stage development of your ADC candidates. Before engaging in costly GMP productions, we can maximize the chances of success by guiding you in the best suited combination of antibody/coupling technology/linker and payload for your specific target.

Global Project Schedule: 18 months



THE COMBINED EXPERTISE IN ADC DESIGN AND PHARMACOLOGY ASSESSMENT

After the generation and the engineering of the antibody candidates, we offer a wide array of conjugation solutions, to ensure the production of homogeneous ADCs incorporating the desired payloads. The retained ADC candidates are characterized pharmacologically using tailored proof-of-concept experiments in the most relevant in vitro and in vivo mouse models. Finally, the developability assessment of the most promising ADC candidates can also be led at MImAbs using in silico modelling tools and analytical biochemical assays.

DRUG-LINKERS



Choose from a wide range of clinically validated drug-linkers (DLs).

DLs containing auristatins, maytansinoids, pyrrolobenzodiazepines (PBDs), duocarmycins or exatecans as warheads are directly available for conjugation (e.g., MC-Val-Cit-PAB-MMAE, Mal-PEG4-VC-DMEA-Seco-Duocarmycin, MC-GGFG-DX8951 or Mal-PEG8-Val-Ala-PAB-SG3200). Alternatively, custom conjugations with different structures can also be evaluated. Typically, we address random conjugations through maleimide chemistry on naked mAbs. Alternatively, the site-specific conjugation can be achieved with cys engineered Ab backbones (THIOMAB) or to other specific residues through enzymes (such as bacterial transglutaminase).

DEVELOPABILITY



Developability profile of your candidates (ADC derisking).

We propose a series of analytical tests to best characterize physico-chemically your most promising candidates. The thermal stability, hydrophobicity or plasma stability (among others) are predictive and reliable attributes of ADC developability that need to be evaluated during pre-clinical development. This pre-CMC characterization is an important tool for ranking the developability of all your candidates.

EFFICACY EVALUATION



The best cell and mouse models to validate ADC efficacy in vitro and in vivo.

Our Pharmacology Team evaluates the *in vitro* efficacy of your candidates in panel of cell lines. The *in vivo* efficacy is evaluated using relevant syngeneic or xenogeneic mouse models or also on PDX models available from Xentech. For a comprehensive preclinical evaluation of your ADCs, pharmacological aspects can also be explored with available engineered mice (human target knock-in mice) or newly created models by JC Discovery.

FROM STANDARD TO CUSTOMIZED SERVICES FOR YOUR ANTIBODY AND ADC LEAD CANDIDATES

JANVIER GROUP
BIOSCIENCES

In a constant and fully transparent dialog, our experts will guide you through our most relevant solutions to develop your leads in the best cost- and time-effective step-by-step process. MImAbs is now part of the Janvier Group.
You may thus benefit from complementary services to further characterize your Abs & ADCs.

R&D solutions for the development of mAbs, ADCs or Bispecifics

- Recombinant mAb generation.
- Generation of mouse or rabbit mAbs libraries and selection through single cell screening Beacon® technology.
- Cloning of VH and VL and sequencing.
- Humanization.
- mAb bioproduction: from mg to gram scale. All formats: naked, mutated Abs or bispecifics.
- Generation and developability of ADCs with a choice of coupling technologies, linkers and payloads. Selection of the best option for your target.
- In vitro mAb validation using direct cytotoxicity, ADCC and ADCC-like assays.
- In vivo validation of mAbs, ADC or bispecifics in relevant syngeneic, genetically engineered or xenogeneic mouse models.

Complementary services within the Janvier Group

- Newly designed engineered mice and rat models (Knock-out or Knock-in models).
- Humanized models (human CD34 reconstituted mice).

JC DISCOVERY®

- Evaluation with a wide range of PDX (Patient-Derived Xenograft) models.

XenTech